Latest News

Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy

Oct

16

2025

Senhwa Biosciences’ CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

Sep

16

2025

Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

Sep

05

2025

Official Statement

Sep

02

2025

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

Aug

07

2025

Senhwa Biosciences announces first patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) pharmacodynamics in patients with advanced solid tumors

Jul

16

2025

Senhwa Biosciences Highlights Breakthroughs in Dual First-in-Class Drug Programs at Annual Shareholders’ Meeting Today

Jun

25

2025

Senhwa Biosciences Shines at G4thering 2025, Reinforcing Global Leadership and Driving International Cooperation

Jun

04

2025